Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bile Duct Inflammation Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study Of Ursolic Acid For Primary Sclerosing Cholangitis

NCT03216876
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Ursolic acid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Evaluation of DHA for the Treatment of PSC

NCT00325013
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Colitis
Interventions
Docosahexaenoic Acid (DHA)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Tuscon, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

NCT02137668
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Biliary Atresia
Interventions
Oral Vancomycin
Drug
Lead sponsor
Sacramento Pediatric Gastroenterology
Other
Eligibility
2 Weeks to 40 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

NCT04678219
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Dietary Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

NCT02704364
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Sacramento, California • San Clemente, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional Results available

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

NCT03890120
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
82
States / cities
Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 28, 2026, 4:58 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed No phase listed Observational

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

NCT03766035
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
SpyGlass DS I - II
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Davis, California • Sacramento, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 28, 2026, 4:58 PM EDT
Completed No phase listed Observational

Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis

NCT02616705
View directory record Official record
Conditions
IgG4-related Sclerosing Cholangitis, IgG4-related Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

NCT03111732
View directory record Official record
Conditions
Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
Interventions
Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 4:58 PM EDT
Completed No phase listed Observational

NPDT Evaluation in Children With CFTR and (PSC)

NCT00179439
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions
nasal potential difference testing
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 28, 2026, 4:58 PM EDT
Withdrawn Not applicable Interventional

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

NCT03046901
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions
Vancomycin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 28, 2026, 4:58 PM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 28, 2026, 4:58 PM EDT
Recruiting Phase 3 Interventional

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Xifaxan to Treat Patients With PSC

NCT01695174
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Xifaxan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

NCT03561584
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Sulfasalazine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
15 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

NCT02653625
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cenicriviroc 150 mg
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 28, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 28, 2026, 4:58 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
40
States / cities
Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 28, 2026, 4:58 PM EDT
Recruiting No phase listed Observational

Primary Sclerosing Cholangitis in Children

NCT04181138
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
2 Years to 25 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 28, 2026, 4:58 PM EDT